iECURE

Executive Summary

iECURE is a privately held, Philadelphia-based biotechnology company pioneering in vivo gene editing to treat devastating rare diseases. Founded in 2021, the company aims to reverse the course of severe genetic conditions by inserting corrective genes directly into patients' cells, offering a potentially one-time curative approach. Their proprietary technology leverages cutting-edge gene editing tools to achieve durable expression of missing or defective proteins. As an early-stage company, iECURE is focused on advancing its lead programs toward clinical development, with a strong emphasis on addressing high unmet medical needs in pediatric rare diseases. The company's innovative platform and patient-centric mission position it at the forefront of the next wave of gene therapy, though it remains pre-revenue and dependent on successful preclinical and clinical outcomes. With a small but dedicated team and collaborative partnerships, iECURE seeks to transform the treatment landscape for conditions currently lacking effective therapies.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program40% success
• Q3 2026Preclinical Data Presentation at Major Conference70% success
• Q3 2026Series A/B Financing Announcement60% success